Metabolic regulation

ImmunoMet Therapeutics Inc. is developing a portfolio of biguanide derivatives that have the anticancer properties of metformin but are better optimized for the indication. Some starve drug-resistant cancers by blocking a metabolic pathway they rely on, while others inhibit metabolism in immunosuppressive cells.

One way cancer cells become resistant to chemotherapy is by switching their primary method of metabolism from glycolysis to oxidative phosphorylation. COO Benjamin Cowen said evidence is mounting that the biguanide metformin can inhibit this method of metabolism...